Floatz logo

Anti-Cd30 Bispecific Antibody-Armed Anti-Cd3-Activated Autologous T-Cells

CD30-Positive Diffuse Large B-Cell Lymphoma

Medical College of WisconsinCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

270 Active assets in the CD30-Positive Diffuse Large B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3A
Evomela
Ruijin Hospital
Phase 4BBB
Axicabtagene Ciloleucel
Ruijin Hospital
Phase 4BBB
PREDNISONE TABLETS
Beth Israel Deaconess Medical Center
Phase 4BBB
Inno-206
Beth Israel Deaconess Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

Anti-Cd30 Bispecific Antibody-Armed Anti-Cd3-Activated Autologous T-Cells is also rated in:

Hodgkins lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
anaplastic large cell lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
primary cutaneous anaplastic large cell lymphomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →